bispecific antibodies

MA strategy deal block push come together form
Biotech

Genmab pays $8B to buy Merus and phase 3 bispecific

Genmab is continuing to build its pipeline of wholly owned cancer assets, this time paying $8 billion for Merus and its bispecific antibody.
James Waldron Sep 29, 2025 5:38am
Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Editor's Corner—Summit must submit to Big Pharma, stat

Sep 10, 2025 2:50pm
BioNTech

BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC

Sep 8, 2025 11:00am
Summit
Favicon Fierce Pharma

Summit's global PD-1xVEGF data show new promising OS trend

Sep 7, 2025 3:30am
graphic image of different colored hands shaking

China-based Novatim notches new deal with another US biotech

Sep 2, 2025 2:36pm
Akeso
Favicon Fierce Pharma

Akeso, Summit's PD-1xVEGF drug meets OS goal for the first time

Aug 26, 2025 11:36am